MicuRx Taps China Links To Progress Improved Oxazolidinone
This article was originally published in PharmAsia News
Multidrug-resistant bacteria have been identified as a major public health threat by the WHO. MicuRx, a Sino-US drug developer, is discovering and developing novel potential first-in-class antibiotics to combat such infections, and is taking an oxazolidinone with expected benefits over same class drugs into Phase III China trials.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.